Delta-8 THC exploded onto the scene in 2019, followed by delta-10 THC, THC-O acetate and HHC in 2020 and 2021.
While state regulatory agencies have opted for a whack-a-mole approach that focuses on controlling one cannabinoid at a time, the federal government has been largely silent on the legal status of hemp-derived cannabinoids.
Marijuana products technically aren’t eligible for federal trademarks because the plant is illegal under the Controlled Substances Act.
But that doesn’t mean cannabis businesses can’t protect their intellectual property and build brand awareness through patents and federal trademarks—the latter is applicable if the application doesn’t involve a plant-touching side of the business.
A group of medical professionals who support rescheduling marijuana have dropped a lawsuit against the U.S. Drug Enforcement Administration that, among other things, accused the agency of rigging the process against changing the drug’s status under federal law.
The possible reclassification of marijuana under the federal Controlled Substances Act is sparking debate about dismantling barriers to interstate commerce and the future of the industry.
If Congress can’t – or won’t – legalize marijuana at the federal level, the least U.S. lawmakers can do is get out of the way of states with adult-use cannabis.
The U.S. Drug Enforcement Administration’s marijuana rescheduling process “remains pending,” according to a new filing.
President Donald Trump’s choices over his first 50 days in office, including appointments to lead the federal drug and health agencies, are sowing serious doubts that marijuana’s status under federal law will change anytime soon.
Because 280E thwarts operational success, it greatly incentivizes people to perpetuate the illicit marijuana market.
Longstanding suspicions that the U.S. Drug Enforcement Administration is adamantly opposed to marijuana rescheduling – and weighted a public process to ensure it could reject moving the drug from Schedule 1 to Schedule 3 under federal law – are confirmed by agency decisions made public during an ongoing lawsuit.
The Trump administration’s plan to cut federal research funding threatens 565 ongoing experiments involving cannabis, according to an MJBizDaily review and interviews with scientists and academics.
The Trump administration is refusing to return more than $1 million of marijuana seized from state-licensed New Mexico cannabis companies at interior Border Patrol checkpoints over the past year, a lawsuit says.
